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ABSTRACT
Obesity is an important health problem both in 
developed and developing countries. Obesity is an 
abnormal increase in body weight due to fat 
deposition. The real cause of obesity is unknown but 
genetic, environmental factors and family eating 
habits, hormonal, and psychological factors have 
roles. Regardless of the origin of the disease, obesity 
develops when caloric intake exceeds the caloric 
needs of the individual. Adipose tissue is not merely a 
fat store, it is metabolically active and also has a 
secretory role. Leptin, synthesized and secreted by 
adipose tissue, regulates the size of adipose tissue. 
Obesity is highly associated with the adult onset of 
diabetes mellitus, coronary heart disease, and 
hypertension.
Extensive efforts must be made and measures must 
be taken to educate people in adapting to healthy 
lifestyles.
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INTRODUCTION
The terms obesity and overweight refer to excess in 
body weight relative to height. Ideal body weight (IBW) 
is associated with the lowest morbidity and mortality. 
Body weight relative to IBW is called the relative 
weight. Overweight is defined as relative weight up to 
20  % above normal and obesity as over 20  % above 
IBW. Body weight is continously distributed in 
populations and it is not easy to define obesity due to 
great variation in lean body mass among individuals of 
the same stature.
Reductions in energy expenditure are the main factors 
responsible for the increase in the prevalance of 
obesity. Consequences of this increase only become
apparent many years later like chronic conditions such 
as arthritis or conditions related to obesity but 
occurring later in life such as cerebrovascular events, 
chronic heart failure or breast cancer in women.
ADIPOSE TISSUE
Adipose tissue (AT) is a specialized connective tissue 
designed for the synthesis, storage and hydrolysis of 
triaclyglcerols (TAG). TAG'S are stored as liquid 
droplets in the cytoplasm; the half life of TAG is only a 
few days. Nearly the entire volume of each adipocyte 
can be occupied by a droplet of TAG. Adipose tissue 
is the main organ of cholesterol storage in the body 
and contains mostly non-esterified cholesterol. 
Adipocytes first appear late in fetal development 
preparatory to postnatal life. Adipose lineage arises 
from the same multipotent stem cell population of 
mesodermal origin. When appropriately induced with 
hormonal agents, committed preadipocytes 
differentiate into adipocytes in culture (1). AT 
comprises about 10% of the body mass of normal 
infants at birth. In the first few months of life, 
adipocytes increase their storage capacity by 
hypertrophy. In nonobese children fat cells decrease 
after age one, whereas it remains hypertrophic in 
obese children. Adipocyte hyperplasia or increase in 
the number of adipose cells appears to occur from 1 
year of age to preadolescence proceeding more 
rapidly in obese children. Thereafter increase in 
adipose tissue occurs by hypertrophy. Very obese 
people have increased number of adipocytes whereas 
moderate obesity is hypertrophic. The latter respond 
better to treatment. In early adulthood, nonobese 
males have 10-15% of body mass as fat, whereas in 
normal females adipose tissue is 15-20%. In a 70 kg 
man adipose tissue weighs approximately 14 kg or 
about half as much as the total muscle mass. In obese 
individuals AT can constitute up to 70% of body weight
(2 ).
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Adipose tissue is found mostly under the skin, in the 
abdominal cavity, in skeletal muscle, around blood 
vessels, and In mammary gland. Although small in 
quantity compared to white adipose tissue (WAT), 
brown adipose tissue (BAT) must also be mentioned 
because of its importance in thermogenesis. Brown 
adipose tissue which is the site of nonshivering 
thermogenesis, is reduced or absent in obese people. 
In fact obesity may be related inpart to a defect in 
thermogenesis (3).
ETIOLOGY OF OBESITY
Obesity is the state of excess strorage of triglyceride 
and exerts important effects on metabolic processes in 
adipose tissue and in other organs. Regulation of 
triglyceride storage involves both neural and endocrine 
factors but primarily reflects the net surplus of caloric 
substrate available to the organism (4).
The cause of most cases of obesity is not known. 
Genetic factors interact with environmental factors. 
Family eating patterns especially In infancy and early 
childhood have important effects (5). However, studies 
done with identical twins reared apart have shown 
evidence for substantial genetic determinacy of 
adipose mass. Studies have also shown that 80% of 
children with two obese parents will be obese, while 
only 14% of children of normal weight parents will be 
obese (6 ). Endocrine diseases such as Cushing's 
disease or hypotyhroidism are rare causes. Obesity 
may also be associated with Klinefelter’s and Turner 
syndromes, male hypogonadism, and castration. 
Hyperinsulism associated with insulinoma can also 
lead to obesity. Insulin resistance is almost always 
associated with obesity. Hypothalamic dysfunction and 
lesions as well as psychological factors lead to obesity. 
Prader-Willi, Bardet-Biedl, Alstrom-Hallgren, 
Frohlich's, Cohen's, Carpenter's Syndromes, 
Hyperostosis Frontalis Interna, and Multiple 
Lipomatosis are all associated with obesity (7).
Several genes at different loci on human and rodent 
chromosomes have been associated with obesity. The 
ob gene is expressed in adipose tissue and plays an 
Important role in regulating body weight in mice. In 
ob/ob mice which become very obese, the ob gene is 
mutated so that no leptin is produced, when given 
leptin the affected mice stop eating and lose weight 
(7). In humans leptin and leptin receptor gene have 
shown linkages to obesity. Apart from mutations in 
leptin and leptin receptor gene, agouti (A) gene, 
carboxypeptidase E (cpE) and tub genes are 
implicated in the obesity of rodent. ASIP (gene symbol 
for human analogous to agouti) has not yet been 
directly linked to human obesity; agouti related protein 
(AGRP) gene product may be a potential distal
mediator of leptin effects in energy homeostasis. To 
date no mutations in human tub analog or cpE have 
been reported in human obesity. Obesity due to 
compound heterozygoticy for mutations in prohormone 
convertase has been recently documented in a 47- 
year old woman (8 ).
BIOCHEMISTRY OF ADIPOCYTES AND 
OBESITY
AT is an organ of metabolism that serves as a 
reservoir of energy rich fatty acids. AT is the main 
store of TAG in the body, most of the TAG produced 
by the liver are transported to the adipose tissue for 
long term storage (9). The TAG stores in the adipose 
tissue continuously undergo lipolysis and 
reesterification and these processes are not the 
forward and the reverse phases of the same reaction 
(Fig. 1). The resultant of these two processes 
determine the magnitude of the free fatty acid (FFA) 
pool in AT and in plasma. It has recently been 
demonstrated that the release of individual FA from 
WAT is highly selective and as a rule FA's are 
preferentially mobilized when they are short, more 
unsaturated, have double bonds close to the terminal 
methyl group of the chain (10). Plasma FFA level has 
important effects on the metabolism of other tissues 
especially liver and muscle. Most of the FA stored in 
AT appears to come from circulating triglyceride-rich 
lipoproteins. The triglycerides of very low density 
lipoproteins (VLDL) and chylomicrons are hydrolyzed
Fig-i : Metabolism of Adipose Tissue
1 5 3
Gülay Hergenç
by lipoprote in  lipase (LPL) located on the cap illa ry  
endothelium  yie ld ing fa tty  acids. Insulin induces LPL 
activity and fac ilita tes entry of g lucose into ad ipocytes 
w here it is converted to g lycero l 3-phosphate . G lycero l
3 -phosphate  prov ides the  g lycery l m oie ty fo r the 
esterification of free  fa tty acids. Because g lycero l 
kinase is low in activ ity  in A T  g lycero l cannot be 
utilized to any great extent in the  esterification of FAs. 
AT can m etabo lize  g lucose by hexosem onophosphate  
pathw ay producing NADPH essentia l for fatty acid 
synthesis. H owever, hum an AT is not an im portant site 
of lipogenesis. Aceta te  derived from  ethanol can also 
be converted into fa tty acids by the ad ipose tissue. 
G lucose also contributes to the synthesis o f FAs but to 
a lim ited extent. In trace llu la r horm one sensitive  lipase 
(HSL) hydro lyzes the stored trig lycerides in A T  and 
FFAs and g lycerol are m obilized into p lasm a. The first 
steps in w h ich  tw o m o les of FAs are re leased  
constitu te  the rate lim iting steps of the hydro lysis w hich 
then rapid ly com ple ted by m onoacylg lycero l lipase. 
Epinephrine, norepinephrine , ACTH, g lucagon, and 
g row th  ho rm one  s tim u la te  the  hyd ro lys is  o f 
trig lycerides. H ow ever ca techo lam ines e ither stim ulate 
or inhib it lipo lysis in fa t cells th rough t the ir action on 
P1.2.3 or a 2'  adrenorecep to rs respective ly (11). The 
sym pathetic nervous system  p lays a centra l ro le in the 
m obilization of FFAs by liberating norep inephrine  in 
AT. M ost o f these  factors increase cAM P which in turn 
activates a prote in  kinase that phosphory la tes inactive 
H SL to  its ac tive  fo rm  (12). In h ib ition  o f 
p h o sh o d ie s te ra se  by c a ffe in e  and th e o p h y llin e  
po ten tia tes the horm onal s tim u la tion  of lypo lys is . 
W hile tyroxine and cortiso l have perm iss ive  effect on 
lipolysis, insulin opposes the horm onal and neural 
stimuli. Insulin prom otes storage of fa t and inhib its 
lipolysis w hen the  blood g lucose and trig lyceride  levels 
rise after a m eal. The principa l action of insulin is to 
inhibit the HSL. Fasting and exerc ise  also prom ote 
lipo lys is . G lu co co rtico id s  p rom o te  lyp o lys is  by 
e ffec ting  syn th e s is  o f new  lipase  by a cA M P - 
independent pa thw ay w hich m ay be inh ib ited  by 
insulin.
AT is a heterogenous m etabolic organ and several 
d ifferences have been observed am ong various fat 
depots. For exam ple, v iscera l ad ipose tissue has a 
h igher lipo lytic activ ity than subcutaneous ad ipose 
tissue  due  to  a co m b in a tio n  o f inc reased  p2- 
ad re n o ce p to r m ed ia ted  ca te ch o la m in e -in d u ce d  
lipolysis and reduced antilipo ly tic  action of insulin in 
the visceral fat depot (11). The fact tha t v iscera l fat 
depot is dra ined by the portal system  to the liver m ust 
be kept in m ind fo r the  a therosclero tic  com plications.
A lthough TAG storage has usually been considered to 
be the m ain function o f AT, m ore recently, it has been 
recognized as a secre tory organ. In addition to  LPL,
ad ipocytes are also a source of cho leste ro l ester 
tra n s fe r p ro te in  (C E TP ), apo  E, es trogen , 
ang iotensinogen, tum or necrosis  fac to r (TNF) as well 
as leptin (13). M urine cu ltu red ad ipocytes have been 
shown to synthesize  and secre te  ad ipsin  w hich is 
hom ologous to hum an p lasm a facto r D and is one of 
the pro te ins invo lved in the  a lte rnate  com plem ent 
pathw ay. C om plem ent C3 and fac to r B are also 
expressed and secre ted  in cu ltu red  ad ipocytes and 
m ouse ad ipose  tissue. A cyla tion  stim ula ting  prote in 
(ASP) is also dem onstra ted  to be p roduced by cu ltured 
hum an d iffe ren tia ted  ad ipocytes. Apart from  having 
m arked effects on ad ipocyte  lipid m etabo lism  as a key 
re g u la to r o f the  T A G  sy n th e tic  p a thw ay , ASP 
stim ula tes g lucose  transpo rt by trans loca ting  g lucose 
transporte rs  (G LU T  1, G LU T  4, and G LU T  3). A SP is 
also produced by m ature  ad ipocytes. N either g lucose 
nor FA s have been show n to have any substantia l 
e ffect on A S P  production . A lthough insu lin  increased 
the  ASP production  tw o-fo ld , add ition  of chylom icrons 
to the cell cu ltu re  m edium  caused a 150-fold increase 
(13).
C a lo ric  im ba lance -excess ive  in take or inadequate  
expend itu re -p rom otes w e igh t gain. The m agnitude of 
w e igh t gain depends on the num ber of ca lo ries not on 
the source of the ca lories. O verw e igh t peop le  tend to 
eat a few  in frequent m eals. Food in take triggers insulin 
and g lu co co rtico id  o u tp u t and th is  p ro m o te s  fat 
accum ula tion  w hich in tu rn  increases leptin secretion
(14,15). In obese hum ans leptin  m R N A  in ad ipocytes 
is show n to  be e levated (16).
L E P T IN
Leptin, a 16 kDa peptide  secre ted  by ad ipocytes, 
regu la tes the  size of the  ad ipose tissue  m ass through 
effects on satie ty  and energy m etabo lism  (17). It is a 
product of the ob (obese) gene  on chrom osom e 7. 
Leptin is h igh ly conserved  in d iffe ren t ve rtebra tes w ith 
approxim ate ly  85%  structra l hom ology in m ouse, rat 
and man (18). Its leve ls co rre la te  w ith body fat content 
in hum ans but the regu la tion  o f leptin leve ls is poorly 
understood. In rodents insu lin  and g lucocortico ids 
seem  to regu la te  the  p roduction  of leptin but there  is 
on ly lim ited ev idence tha t th is  occurs in hum ans (19). 
There are som e stud ies show ing tha t p lasm a leptin 
level co rre la tes to  insu lin  secre tion  (20). O ther studies 
show  that leptin leve ls are not regu la ted by insulin
(21). Leptin is a sa tie ty  factor; it con tro ls  (supresses) 
a p p e tite  th ro u g h  its w id e s p re a d  d is tr ib u tio n  of 
recep to rs . Lep tin  recep to r (LE P R  or O b-R ) is a 
m em ber o f the  gp 130 fam ily  o f cy tok ine  receptors 
w hich are know n to s tim u la te  gene  transcrip tion  via 
activation o f cy toso lic  s ignal transduce r and activa tor 
o f tra n s c rip tio n  (S T A T ) p ro te in s  and s tim u la te
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transcrip tion  through in terleukin  6 responsive gene 
e le m e n ts  (22). T he  S TA T  p ro te ins  b ind to 
phosphotyros ine  res idues in the cytop lasm ic dom ain 
o f the  lig a n d -a c tiv a te d  re ce p to r w he re  they  are 
phosphory la ted. The activa ted STAT prote ins dim erize 
and trans loca te  to the  nucleus w here  they bind DNA 
and activa te  transcrip tion . L inkage of m arkers flanking 
LEPR and acute insu lin  re lease and obesity have 
recently been reported. Leptin m ight be linked to food 
in take  th ro u g h  a p p e tite  s tim u la tin g  hypo tha lam ic  
pep tide  neu ro p e p tid e  Y (N PY). It is know n that 
hypotha lam ic cen te rs regu la te  appetite  (23). To reach 
brain, c ircu la ting  leptin m ust cross the blood-brain 
barrier. S tud ies show  that leptin is transported intact 
from  blood to brain by a saturab le  system  (24). In 
s tud ies done w ith ob/ob m ice showed that leptin 
d e fic ie ncy  led to  h yp e rg lyce m ia  and the 
overexpression  of hypotha lam ic NPY that is im plicated 
in the pa thogenes is  o f obesity (25). P lasm a leptin 
levels are e leva ted  in m ost overw eight individuals; 
obesity  m ay be associa ted w ith leptin resistance (26). 
Satie ty cen te r is insensitive  to endogenous leptin 
production  and th is  can be one of the fundam ental 
m echan ism s In obesity  (27). W eight loss reduces 
serum  leptin levels (28).
Leptin adm in is tra tion  in the ob/ob m ouse resulted in 
w e igh t loss by reduction  of food intake and increased 
energy expend itu re  (29).
Leptin d im in ishes insu lin  secre tion  and induces insulin 
res is tance (30). Type II d iabetic  patients treated with 
insu lin  had bo th  ra ised  in su lin  and leptin 
concen tra tions (31). Leptin a lso appears to regulate 
therm ogenes is  (32).
Sex horm ones m ay have an effect on leptin synthesis 
because obese w om en have h igher ob m RNA levels 
than obese man (33). Levels are 3 tim es as high in 
w om en as in men. C ircu la ting  leptin is inversely related 
to age (34). O b/ob m ice tha t have a congenita l 
absence of leptin are infertile . Results of leptin treated 
m ice  in d ica ted  th e  ro le  o f lep tin  in s tim u la ting  
reproductive  endocrine  system  (35).
M E A S U R I N G  O B E S IT Y
S o p h is tica te d  te ch n iq u e s  like  body dens ity  
m easu re m e n t, iso to p ic  co m p a rtm e n ta liza tio n , 
u ltrasonography, and m agnetic resonance im aging 
have been used to m easure  body fat in reseachers 
(36). M ore practic le  ind ices express the re la tionship of 
w e igh t/he igh t ratio. W eight in k ilogram s d iv ided by 
square of he ight in m eters is called the body m ass 
index (BM I or Q uete le t index); height d ivided by cube 
root o f w e igh t is ca lled the pondera l index. The BMI
corre la tes best w ith body com position. The distribution 
of adipose m ass between the trunk and the gluteal 
reg ion can be described  using the ra tio  o f the 
c ircum ference at the w a ist to that at the hips. This ratio 
falls betw een 0.7 and 0.85 in norm al distrubution. BMI 
is a m easure of general ad iposity, whereas w aist to hip 
ratio or regional skinfo ld th ickness are com m only used 
to m esaure abdom inal or v isceral adiposity that shows 
a regional fat d istribution. Densitom etry Is considered 
as the best m ethod for m easuring body fatness and 
co rre la tio n  be tw een BMI w ith  dens itom e try  is 
a pp rox im a te ly  0 .6  (37). S k in fo ld  th ickness  when 
m esaured at the proper sites with constant tension 
ca lipers is also a useful index of fat d istribution. Adults 
are considered obese if skin fo lds exceed 19 mm for 
men and 30 mm for w om en at the m idtriceps level or 
22 mm for m en and 27 mm for w om en at the 
subscapular level. However, it m ust be taken into 
account tha t these num bers represent the upper 20% 
in the United States population (6).
In 1990, W H O  accepted obesity as body mass index 
(BM I) o f 30 kg /m 2 o r m ore (38). The average  
p reva lence  of o bes ity  am ong E uropean cen te rs  
partic ipating in the W H O -M O N IC A  study between 
1983 and 1986 was about 15% in men and 22%  
w om en (38).
O B E S IT Y  A N D  C O R O N A R Y  A R T E R Y  
D IS E A S E  R IS K
O besity  increases the  risk of a the rosc le ros is  by 
influencing the action of insulin and its concentration in 
blood (39). Obese ind iv iduals d isp lay some insulin 
resistance and have increased insulin production and 
h ype rinsu linem ia  a ssoc ia ted  w ith  increased  
concentrations of VLDL and recreased concentration 
of HDL (40). It has been hypothesized tha t the insulin 
resistance associated w ith visceral fa t accum ulation is 
the m ediator fo r excess risk associa ted w ith obesity 
(41). Age related decreases in dehydroepiandosterone 
su lfa te  (D HEA) In assoc ia tion  w ith  increases in 
obesity, insulin resistance and a therosclerosis is well 
known (42).
O besity is strongly associa ted w ith card iac risk factors 
including elevated blood pressure, g lucose into lerance 
and dyslip idem ia  (43). C linical tria ls have indicated 
that w eight loss s ign ificantly  im proves these risk 
profiles. Those patients who are m ore than 20%  above 
the m idrange of desirab le  w e igh t may benefit from 
w eight reduction, particu larly if associa ted with other 
risk factors. However, large fluctuations in weight, 
e ither up and down, m ay also increase the risk for 
CHD (4). All patients fo llow ing m yocardia l infarction 
should be on Step II Am erican Heart Associa tion Diet
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with ca loric  restriction to avoid w e igh t gain. W eight 
loss can be better m ainta ined w ith a regular m oderate 
exercise program .
Som e but not all ep idem io log ica l s tud ies have shown 
obesity as an independent risk fac to r fo r coronary 
heart d isease both in men and w om en. M ethodolog ic 
p rob lem s like  no t ta k in g  fa t d is tr ib u tio n  in to  
co n s id e ra tio n  m ay a cco u n t fo r the  co n tra d ic to ry  
findings (44). Abdom ina l ad iposity  con fe rs additional 
risk for CHD. Abdom ina l ad iposity  or w /h is an index of 
an androgenic fat d is tribu tion  and strong ly corre la te  
with h igher insulin levels and insulin resistance. Aging, 
sex horm one, genetic  and d ie tary facto rs and physical 
inactivity m ay induce viscera l fat accum ula tion  (45). 
V isceral fat is characterized by its high lipogenic 
activity as well as its accelerated lipo lytic activity. High 
levels of portal free fa tty acids may eventua lly  resu lt in 
an enhancem ent o f hepatic  trig lyceride  synthesis, 
causing hyperlip idem ia. High portal FFA levels would 
a lso  induce  insu lin  res is tance , th e re b y  caus ing  
g lucose  in to le ra n ce  and d ia b e te s  m e llitu s  (46). 
O bes ity  is c lo se ly  a ssoc ia ted  w ith  m u ltip le  lip id  
abnorm alities (47). H igher BMI is associa ted w ith 
low er H D L -ch o le s te ro l and h ighe r tr ig lyce rid e s ; 
e levated w a ist-h ip  ratio is associa ted w ith increased 
cholestero l, trig lycerides, apo B and decreased HDL-c 
in all age groups o f both m en and w om en. O bese 
people have increased synthetic rates for cholestero l 
and b ile acids. W hen obese peop le  lose w e igh t 
trig lycerides decrease first, then HDL-c increases (10- 
20% ), LDL-c show s no change (48). W /H has been 
found to be a s tronger pred ic tor of CHD com pared to 
BMI. In a m ultivaria te  analysis, w om en in the h ighest 
fertile  o f W /H w ere found to have a re la tive risk o f 3.3 
fo r dea th  from  CHD . E ven a fte r c o n tro llin g  fo r 
hypertension and d iabetes, W /H rem ained predictive. 
W om en w ith noncentra l obesity  had m ore favorab le  
blood pressure, fasting g lucose, and lipid va lues than 
centra lly obese w om en. In men noncentra l obesity is 
also associa ted w ith CHD and risk.
M A N A G E M E N T  O F  O V E R W E I G H T
T re a tm e n t o f o bes ity  is d iffic u lt; p a tience  and 
persistence is needed. Acceptab le  w e igh t ranges by 
height in adults are shown in T ab le  I. A d ie tic ian  or 
o ther nutrition or health professiona l can play an 
im portant role in assisting the patient. The benefits of 
w e ight loss should be em phasized. Perscrip tion of a 
ca lorie  restricted lipid lowering d ie t w ill be necessary. 
It is helpful for the patient to begin a m eal w ith a 
helping of very low ca lorie  or bu lky food, such as c lear 
soup or a m ixed or green salad w ith little  or no oil. 
E nergy dense  foods  m ust be m in im ized . For 
ind ividuals who consum e alcoholic beverages, one to 
two drinks a day m ay be included as part o f the ca lorie  
a llowance.
Table I. Acceptable Body Weights in Adults
Acceptable Weight Range in kg
Height
(Without Full Clothing)
in m
(Without Shoes) Men Women
1.46 42-53
1.48 42-54
1.50 43-55
1.52 44-57
1.54 44-58
1.56 45-58
1.58 51-64 46-59
1.60 52-65 48-61
1.62 53-66 49-62
1.64 54-67 50-64
1.66 55-69 51-65
1.68 56-71 52-66
1.70 58-73 53-67
1.72 59-74 55-69
1.74 60-75 56-70
1.76 62-76 58-72
1.78 64-79 59-74
1.80 65-80
1.82 66-82
1.84 67-84
1.86 69-86
1.88 71-88
1.90 73-90
1.92 75-93
Optimal bedy mass index 20.1-25.0 18.7-23.8
(weight in kg/height in m2)
Source: Data from the 1992 EAS guidelines.
Note: Desirable waist/hip ratio is <0.9 in men, <0.8 in women; the 
minimum level lor diagnosing obesity is 20% above the upper limit of 
the acceptable range.
A decrease of about 500 kcal per day w ill result in the 
loss of 0.5 kg per w eek. A de fic it about 3500 kcal is 
needed to  lose 0.5 kg.
A n exe rc ise  p rog ram  a c c o rd in g  to  the  pa tie n t's  
p re ference and /o r level o f fitness and health status is 
necessa ry . P rog ress ive ly  b risk  w a lk ing  fo r 30-45 
m inutes, 5-7 days per w eek is a useful option to be 
con tinued  a fte r ta rge t w e igh t is a tta ined  to ass is t in 
w e ig h t m a in te n a n ce . V a rio u s  su rg ica l tre a tm e n t 
m ethods fo r obes ity  are now  ava ilab le  w hen no 
success w ith d ie t and life s ty le  m od ifica tion  is atta ined. 
T he  m ain ind ica tion  fo r ope ra tive  trea tm en t is m orbid 
obesity  (B M I>40 kg /m 2) or severe  obesity  (BM I>35 
kg /m 2). The m odern surg ica l m ethods are a im ed at 
lim ita tion  o f oral in take  per m ea l-ve rtica l banded 
gastrop lasty  and gastric  band ing, lim ita tion  of oral 
in take and induction  o f dum p ing -R oux-en -Y  gastric  
bypass or induction  o f se lective  m a ld igestion  and 
m alabsorp tion , as w ith b iliopancrea tic  bypass (49). All 
b a ria tr ic  su rg ica l tre a tm e n ts  have  peri or post
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absorp tive  com p lica tions re la ted to the operation. 
O rlista t o ffe rs a new  therapeu tic  approach for the 
trea tm ent o f m odera te  to severe obesity. Orlistat, a 
chem ica lly  syn thesized  deriva tive  of lipstatin which is a 
natural p roduct o f S teptom yces toxtric in i, is a potent 
inh ib itior o f in testina l lipases. In hum ans 400 mg daily 
dose results in 35%  inh ib ition of d ie tary fat. Its efficacy 
has been docum ented  in well contro lled, long-term  
studies. A long w ith  w e igh t loss, O rlis ta t also favourably 
a ffects b lood p ressure  and g lucose and insulin levels 
in obese ind iv idua ls and in obese type 2 d iabetic 
patients (50).
To conclude: diet, behavio r therapy, physical exercise 
and surg ica l the rapy w hen im plicated are used to deal 
w ith obesity  w hich is an increasing health problem  in 
m ost deve loped and deve lop ing  countries.
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